0001104659-23-075015.txt : 20230627 0001104659-23-075015.hdr.sgml : 20230627 20230627081215 ACCESSION NUMBER: 0001104659-23-075015 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230622 FILED AS OF DATE: 20230627 DATE AS OF CHANGE: 20230627 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Brenner Martin CENTRAL INDEX KEY: 0001770235 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-35023 FILM NUMBER: 231044014 MAIL ADDRESS: STREET 1: C/O PFENEX INC. STREET 2: 10790 ROSELLE STREET CITY: SAN DIEGO STATE: CA ZIP: 92121 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: iBio, Inc. CENTRAL INDEX KEY: 0001420720 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 262797813 STATE OF INCORPORATION: DE FISCAL YEAR END: 0630 BUSINESS ADDRESS: STREET 1: 600 MADISON AVENUE, SUITE 1601 CITY: NEW YORK STATE: NY ZIP: 10022-1737 BUSINESS PHONE: 302 355-0650 MAIL ADDRESS: STREET 1: 600 MADISON AVENUE, SUITE 1601 CITY: NEW YORK STATE: NY ZIP: 10022-1737 FORMER COMPANY: FORMER CONFORMED NAME: iBioPharma, Inc. DATE OF NAME CHANGE: 20080806 FORMER COMPANY: FORMER CONFORMED NAME: InB:Biotechnologies, Inc. DATE OF NAME CHANGE: 20071210 4 1 tm2319771-1_4seq1.xml OWNERSHIP DOCUMENT X0407 4 2023-06-22 0 0001420720 iBio, Inc. IBIO 0001770235 Brenner Martin C/O IBIO, INC. 8800 HSC PARKWAY BRYAN TX 77807 0 1 0 0 See Remarks 0 Common Stock 2023-06-22 4 D 0 75833 0 D 177578 D Common Stock 2023-06-26 4 A 0 75833 0 A 253411 D Consists of 75,833 shares of iBio, Inc. (the "Company") common stock, $0.001 par value per share (the "Common Stock") represented by 75,833 restricted stock units ("RSUs") granted under the Company's 2020 Omnibus Equity Incentive Plan, (the "2020 Plan") that expired prior to vesting. Consists of 75,833 shares of the Company's common stock, represented by 75,833 RSUs granted under the Company's 2020 Plan. Each RSU represents a contingent right to receive one share of Common Stock. The 75,833 RSUs vest pro rata over a seven-month period, such vesting to terminate if Dr. Brenner is no longer the Company's Chief Executive Officer Chief Executive Officer and Chief Scientific Officer /s/ Martin Brenner 2023-06-27